Frontline brentuximab vedotin in breast implant‐associated anaplastic large‐cell lymphoma

Key Clinical Message We report a woman who developed BIA‐ALCL 9 years after saline implant placement. The lymphoma manifested as a mass lesion associated with axillary lymphadenopathy. She was successfully treated with brentuximab vedotin with minimal toxicity. Brentuximab vedotin may be a promising frontline therapeutic modality for patients with BIA‐ALCL. Breast implant‐associated anaplastic large cell lymphoma (BIA‐ALCL) is a rare peripheral T‐cell lymphoma. BIA‐ALCL presenting with a capsular mass show shorter survival despite implant removal followed by CHOP‐like chemotherapy. We present a patient with BIA‐ALCL successfully treated with frontline brentuximab vedotin.